8-K filed Aug 6, 2026 at 08:03 ET
Novavax reported Q2 2026 total revenue of $57M, a 76% decline YoY from $239M, driven by the absence of a $175M BLA milestone and $27M Takeda amendment that benefited the prior year. The company posted a GAAP net loss of $53M ($-0.32 per share) versus net income of $107M in Q2 2025. However, Novavax raised its full-year 2026 Adjusted Total Revenue framework to $235M-$275M (from $230M-$270M) and improved GAAP combined R&D and SG&A expense guidance, signaling confidence in its partnership-driven strategy and cost discipline despite the quarterly revenue drop.